A detailed history of Mariner, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Mariner, LLC holds 18,018 shares of EXEL stock, worth $593,873. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,018
Previous 18,931 4.82%
Holding current value
$593,873
Previous $425,000 9.88%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.96 - $27.6 $20,049 - $25,198
-913 Reduced 4.82%
18,018 $467,000
Q2 2024

Aug 13, 2024

BUY
$20.34 - $23.73 $5,390 - $6,288
265 Added 1.42%
18,931 $425,000
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $36,164 - $42,906
1,793 Added 10.63%
18,666 $442,000
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $59,290 - $74,320
-3,080 Reduced 15.44%
16,873 $404,000
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $40,231 - $48,049
2,113 Added 11.84%
19,953 $435,000
Q2 2023

Aug 11, 2023

BUY
$18.17 - $20.48 $27,727 - $31,252
1,526 Added 9.35%
17,840 $340,000
Q1 2023

May 12, 2023

SELL
$16.3 - $19.41 $162,576 - $193,595
-9,974 Reduced 37.94%
16,314 $316,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $32,597 - $37,892
2,179 Added 9.04%
26,288 $422,000
Q3 2022

Nov 10, 2022

BUY
$15.68 - $22.27 $501 - $712
32 Added 0.13%
24,109 $378,000
Q2 2022

Aug 15, 2022

SELL
$17.44 - $23.16 $21,643 - $28,741
-1,241 Reduced 4.9%
24,077 $501,000
Q1 2022

May 13, 2022

BUY
$17.03 - $22.67 $59,605 - $79,345
3,500 Added 16.04%
25,318 $574,000
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $22,191 - $30,653
1,401 Added 6.86%
21,818 $399,000
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $25,900 - $33,591
1,589 Added 8.44%
20,417 $432,000
Q2 2021

Aug 24, 2021

SELL
$17.95 - $25.56 $14,503 - $20,652
-808 Reduced 4.11%
18,828 $343,000
Q1 2021

May 07, 2021

SELL
$20.53 - $25.22 $17,204 - $21,134
-838 Reduced 4.09%
19,636 $443,000
Q4 2020

Feb 16, 2021

BUY
$18.39 - $24.8 $110,634 - $149,196
6,016 Added 41.61%
20,474 $411,000
Q3 2020

Nov 13, 2020

SELL
$20.67 - $26.94 $10,272 - $13,389
-497 Reduced 3.32%
14,458 $354,000
Q2 2020

Aug 14, 2020

BUY
$16.46 - $27.42 $17,315 - $28,845
1,052 Added 7.57%
14,955 $355,000
Q1 2020

May 14, 2020

SELL
$14.46 - $21.8 $30,279 - $45,649
-2,094 Reduced 13.09%
13,903 $239,000
Q4 2019

Feb 13, 2020

SELL
$15.15 - $18.89 $21,740 - $27,107
-1,435 Reduced 8.23%
15,997 $282,000
Q3 2019

Nov 13, 2019

BUY
$17.68 - $22.65 $5,038 - $6,455
285 Added 1.66%
17,432 $308,000
Q2 2019

Aug 14, 2019

BUY
$18.93 - $24.75 $50,391 - $65,884
2,662 Added 18.38%
17,147 $366,000
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $283,906 - $358,648
14,485 New
14,485 $345,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.